8-K: ImmunityBio Reports Record Q2 Revenue, Pipeline Advances

ImmunityBio announced record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year, alongside significant progress in its clinical pipeline and regulatory milestones.

Summary

• ImmunityBio reported record net product revenue of $50.7 million for the second quarter of 2026, a 92% increase year-over-year and a 15% increase sequentially.
• First-half 2026 net product revenue reached $94.8 million, up 121% compared to the first half of 2025.
• The company has achieved its eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA.
• The United Arab Emirates granted broad marketing authorization for ANKTIVA in July 2026.
• The FDA accepted a supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG, with a target action date of January 6, 2027.
• ImmunityBio ended the quarter with over $357.4 million in cash, cash equivalents, and marketable securities.
• Research and Development (R&D) expenses increased to $60.8 million in Q2 2026, and Selling, General, and Administrative (SG&A) expenses rose to $51.8 million.
• Net loss attributable to common stockholders was $230.4 million for Q2 2026, compared to $92.6 million in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth and pipeline advancements, though significant net losses and increased expenses warrant attention.

Positives

• Record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially.
• First-half 2026 net product revenue of $94.8 million, up 121% year-over-year.
• Eighth consecutive quarter of sequential revenue growth for ANKTIVA.
• Broad marketing authorization for ANKTIVA granted in the United Arab Emirates.
• FDA acceptance of sBLA for ANKTIVA plus BCG with a PDUFA target action date of January 6, 2027.
• Strong cash position of $357.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
• Exclusive U.S. rights secured for intravesical Tokyo-172 BCG development and commercialization.
• Continued advancement across the clinical pipeline with multiple milestones anticipated.

Negatives

• Net loss attributable to ImmunityBio common stockholders was $230.4 million for Q2 2026, a significant increase from $92.6 million in Q2 2025.
• Total operating costs and expenses increased to $112.9 million in Q2 2026 from $97.7 million in Q2 2025.
• Research and Development expenses increased by $5.6 million to $60.8 million in Q2 2026.
• Selling, General, and Administrative expenses increased by $9.5 million to $51.8 million in Q2 2026.
• Other expense, net increased substantially to $168.7 million in Q2 2026 from $21.0 million in Q2 2025, largely due to non-cash changes in fair value of liabilities.

Risks

• The preliminary financial results may differ from final reported results.
• Risks and uncertainties regarding participation, enrollment, and potential results from clinical trials.
• Uncertainty regarding whether clinical trials will result in registrational pathways or if data will be accepted by regulatory agencies.
• Ability to fund ongoing and anticipated clinical trials.
• Potential delays in product availability and regulatory approvals.
• Potential product shortages or manufacturing disruptions impacting availability and timing.
• Ability to scale manufacturing and commercial supply operations.
• Ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights.

Future Outlook

Multiple regulatory, clinical, and data milestones are anticipated over the next 12 months, including a planned 2026 sBLA submission for the Phase 2B QUILT-2.005 trial. The company expects continued adoption of ANKTIVA and aims to expand its global commercial footprint and clinical pipeline.

Management Comments

• "Our record quarterly net product revenue of $50.7 million and eighth consecutive quarter of sequential growth reflect continued physician adoption of ANKTIVA and disciplined commercial execution."
• "At the same time, we continue to invest in expanding ANKTIVAs global commercial footprint while advancing a focused late-stage clinical pipeline that we believe will create additional opportunities across multiple oncology indications."
• "With $357.4 million in cash and cash equivalents, and marketable securities, we are well-positioned to support both our commercial and clinical priorities."
• "The continued adoption of ANKTIVA in clinical practice reinforces the potential of our IL-15 receptor agonist platform to activate the bodys natural killer and T cells to fight cancer."
• "As we continue generating clinical evidence across multiple tumor types, including bladder cancer, lung cancer, and hematologic malignancies, we remain focused on expanding the potential applications of this platform to address additional areas of significant unmet medical need."

Industry Context

StockSavvy.ai notes that ImmunityBio's strong revenue growth in ANKTIVA aligns with the broader trend in the oncology market towards targeted immunotherapies and personalized medicine. The company's focus on bladder cancer and other solid tumors addresses significant unmet needs, and the expansion of regulatory approvals globally is a key indicator of market acceptance.

Related Party Transactions

• Non-cash changes in the fair value of related-party convertible note, warrant liabilities, and other derivative liabilities significantly impacted net loss.
• Interest expense related to revenue interest liability and interest expense related to a related-party convertible note are noted.

Stakeholder Impact

• Shareholders benefit from strong revenue growth and pipeline advancements, but face increased net losses and operating expenses.
• Patients may benefit from expanded access to ANKTIVA and potential new indications.
• Creditors and noteholders are impacted by the company's financial performance and the valuation of related-party convertible notes.

Next Steps

• Continue advancing ANKTIVA's global commercial footprint.
• Advance focused late-stage clinical pipeline programs.
• Submit sBLA for the Phase 2B QUILT-2.005 trial in BCG-nave NMIBC in 2026.
• Develop, import, and commercialize intravesical Tokyo-172 BCG in the U.S.

Key Dates

Recommendation

The strong revenue growth and pipeline progress are positive indicators. However, the significant increase in net loss, coupled with rising R&D and SG&A expenses, alongside the substantial impact of non-cash fair value adjustments on liabilities, necessitates a cautious approach. While the company is well-positioned financially, the path to profitability remains long, warranting a 'hold' recommendation pending further clarity on clinical trial outcomes and expense management.

Keywords

ANKTIVA, NMIBC, bladder cancer, oncology, immunotherapy, biotechnology, clinical trials, revenue growth